Patel Sanj K's Form 4 filing
Kiniksa Pharmaceuticals International, plc (KNSA) · filed Apr 8, 2026
- Accession no.
- 0001532218-26-000004
- Filed
- Apr 8, 2026
- Trade date
- Apr 6-7, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $364.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Patel Sanj KCIK 0001532218 | Director, Officer (CHAIRMAN & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 6, 2026 | Class A Ordinary Share | MOption exerciseAcquired | +7,278 | $10.36 | +$75,400.08 | 7,278 | Direct | |
| Apr 6, 2026 | Class A Ordinary Share | SSaleDisposed | −7,278 | $50.01 | −$363,972.78 | 0 | Direct | |
| Apr 7, 2026 | Class A Ordinary Share | MOption exerciseAcquired | +9,991 | – | – | 81,005 | Indirect | |
| Apr 7, 2026 | Class A Ordinary Share | FTax withholdingDisposed | −4,831 | $48.94 | −$236,429.14 | 76,174 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 6, 2026 | Class A Ordinary Share | MOption exerciseDisposed | −7,278 | $0.00 | $0 | 431,904 | Direct | |
| Apr 7, 2026 | Class A Ordinary Share | MOption exerciseDisposed | −9,991 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.